- Home
- ENTG vs INCY Comparison
ENTG vs INCY Comparison
Compare ENTG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTG
- INCY
- Stock Information
- Founded
- ENTG 1966
- INCY 1991
- Country
- ENTG United States
- INCY United States
- Employees
- ENTG N/A
- INCY N/A
- Industry
- ENTG Plastic Products
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ENTG Industrials
- INCY Health Care
- Exchange
- ENTG Nasdaq
- INCY Nasdaq
- Market Cap
- ENTG 11.7B
- INCY 13.0B
- IPO Year
- ENTG 2000
- INCY 1993
- Fundamental
- Price
- ENTG $87.25
- INCY $83.10
- Analyst Decision
- ENTG Buy
- INCY Buy
- Analyst Count
- ENTG 11
- INCY 20
- Target Price
- ENTG $106.18
- INCY $80.31
- AVG Volume (30 Days)
- ENTG 2.5M
- INCY 1.6M
- Earning Date
- ENTG 11-03-2025
- INCY 10-28-2025
- Dividend Yield
- ENTG 0.46%
- INCY N/A
- EPS Growth
- ENTG 60.99
- INCY 900.04
- EPS
- ENTG 1.95
- INCY 4.37
- Revenue
- ENTG $3,223,108,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- ENTG $0.70
- INCY $16.26
- Revenue Next Year
- ENTG $8.09
- INCY $11.07
- P/E Ratio
- ENTG $44.74
- INCY $19.02
- Revenue Growth
- ENTG N/A
- INCY 18.87
- 52 Week Low
- ENTG $60.75
- INCY $53.56
- 52 Week High
- ENTG $117.88
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- ENTG 60.67
- INCY 49.53
- Support Level
- ENTG $78.17
- INCY $84.54
- Resistance Level
- ENTG $82.89
- INCY $87.10
- Average True Range (ATR)
- ENTG 3.00
- INCY 1.78
- MACD
- ENTG 0.34
- INCY -0.64
- Stochastic Oscillator
- ENTG 87.30
- INCY 5.42
About ENTG Entegris Inc.
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.